Eosinophilic Esophagitis (EoE) Research Studies

Eosinophilic Esophagitis (EoE) research studies currently enrolling new participants.

Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis (EoE) - TREET Trial

Currently enrolling

Purpose: To determine whether oral viscous budesonide (OVB) or fluticasone metered dose inhaler (MDI) most effectively treats EoE by improving histologic findings and symptoms, which medication provides a more durable treatment response, and whether biomarkers can predict treatment response.
Principal Investigator:
Evan Dellon, MD MPH
Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Visit ClinicalTrials.gov to learn more about this study: Budesonide Versus Fluticasone for Treatment of EoE

Clinicaltrials.gov


Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

CEGIR

Interested participants can join the contact registry through the Rare Diseases Clinical Research Network. Please follow the link: RareDiseasesNetwork.org

Purpose: To learn about eosinophilic gastrointestinal disorders (EGIDs) and support individuals with the disorders by building a network of patients, researchers, and health care professionals.
Principal Investigators: Evan Dellon, MD MPH at UNC. Marc Rothenberg, MD, PhD at Cincinnati Children's Hospital
Sponsor:
Cincinnati Children's Hospital


Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

Currently enrolling by invitation only

Purpose: To learn about eosinophilic esophagitis (EoE) and find a better and less invasive way other than endoscopy to diagnose EoE.
Principal Investigator:
Evan Dellon, MD MPH
Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Visit ClinicalTrials.gov to learn more about this study: Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

Clinicaltrials.gov


UNC Eosinophilic Esophagitis (EoE) Patient Registry

Currently enrolling by invitation only

Purpose: To learn about eosinophilic esophagitis (EoE) in children, adolescents, and adults. 
Principal Investigator:
Evan Dellon, MD MPH
Sponsor:
University of North Carolina at Chapel Hill

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis - RPC02-201

Enrollment closed

Purpose: To test RPC4046, an investigational drug in development by Receptos, Inc. for the potential treatment of Eosinophilic Esophagitis (EoE).
Principal Investigator:
Evan Dellon, MD MPH
Sponsor:
Receptos, Inc.

Visit ClinicalTrials.gov to learn more about this study: Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

Clinicaltrials.gov


Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge

Currently enrolling new subjects

Purpose: To assess the safety, acceptability, and accuracy of Cytosponge for diagnosis and monitoring of Eosinophilic Esophagitis (EoE) in comparison to endoscopy with biopsy as the gold standard.
Principal Investigator:
Evan Dellon, MD MPH
Sponsor and Collaborators:
C.U.R.E.D. Foundation, Mayo Clinic, University of Cambridge

Visit clinicaltrials.gov to learn more about this study: Diagnosis and Monitoring of EoE Using Cytosponge

Clinicaltrials.gov


iDiet: Application of a Novel Allergen-Specific Immune Signature-Directed Approach to Dietary Elimination Therapy in Patients with EoE

Currently enrolling by invitation only

Purpose: To see if a new way to test for food allergies can help people with Eosinophilic Esophagitis (EoE) learn if certain foods make the disease worse.
Principal Investigator:
Evan Dellon, MD MPH
Sponsor: UNC Team Translational Science Award

Visit clinicaltrials.gov to learn more about this iDiet study

Clinicaltrials.gov


A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients with Active Eosinophilic Esophagitis (EoE) - R668-EE-1324

Currently enrolling

Purpose: To evaluate the the safety and effectiveness of dupilumab
Principal Investigator:
Evan Dellon, MD MPH
Sponsor: Regeneron Pharmaceuticals Inc

Visit clinicaltrials.gov to learn more about this Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE)

Clinicaltrials.gov


Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) with Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study - SHP621-301

Currently enrolling

Purpose: To evaluate the the safety and effectiveness of oral budesonide suspension (OBS)
Principal Investigator:
Evan Dellon, MD MPH
Sponsor: Shire

Visit clinicaltrials.gov to learn more about this Study of OBS in Adolescent and Adult Subjects

Clinicaltrials.gov


A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) with Eosinophilic Esophagitis (EoE) - SHP621-302

Currently enrolling by invitation only

Purpose: To evaluate the the long term safety and effectiveness of oral budesonide suspension (OBS)
Principal Investigator:
Evan Dellon, MD MPH
Sponsor: Shire

Visit clinicaltrials.gov to learn more about this Study of Long-Term OBS in Adolescent and Adult Subjects

Clinicaltrials.gov


Please contact us for more information regarding any of the above active CEDAS research studies:

Return to top of page